TREMFYA® is a prescription medicine used to treat adults and children 6 years and older who also weigh at least 88 pounds (40 kg) with moderate to severe plaque psoriasis who may …

At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured. A …

We would like to show you a description here but the site won’t allow us.

VISIT JANSSEN GLOBAL Home › CAR-T Therapy Cilta-cel Shows Early, Deep and Durable Responses in Heavily Pretreated Multiple Myeloma

May 21, 2019 · VATO® [Prescribing Information]. Titusville, NJ: Janssen treatment-resistant depression: a subgroup analysis of the SUSTAIN-3 study Phar aceuticals, Inc. up to 6.5 years. …

We look forward to sharing more with you about TREMFYA ® (guselkumab). In the meantime, if you have any questions, feel free to call a Janssen CarePath Care Coordinator at …

Janssen Pharmaceuticals, Inc. 2024 02/24 cp-420113v1 concerns about patients receiving SPRAVATO®. and current referring HCPs and keep track of communications that are sent to …

The information in this toolkit is meant to be educational to help inform your communications. Your use of these materials is not an endorsement by Johnson & Johnson of your treatment center. …

Janssen Submits Applications in U.S. and EU Seeking Approval of DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj)/ DARZALEX® (daratumumab) Subcutaneous (SC) …

This ADR is authorized to distribute the products listed below 115 items found, displaying 101 to 115